Lupin rolls out Nasal spray for rhinorrhea relief in US

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older.

In January 2025, the Medical Dialogues team reported that Lupin had received USFDA approval for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution (0.06%).

Later, in February 2025, Lupin received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide Nasal Solution, 0.03% (21 mcg/spray), paving the way for this dual product launch.

Read also: Lupin bags USFDA nod for Ipratropium Bromide Nasal Solution for rhinorrhea

According to IQVIA MAT data (May 2025), Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of USD 63 million in the U.S. 

Read also: USFDA okays Lupin Prucalopride Tablets for chronic idiopathic constipation

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally. 

Read also: Lupin secures USFDA approval for Loteprednol Etabonate Ophthalmic Gel